Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 12, 2012

Novel Treatment for Most Common Type of Lung Cancer

  • The FDA OK’d Celgene’s Abraxane® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. The drug was approved for use in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

    “Non-small cell is the most common type of lung cancer, the leading cause of cancer death in the United States,” said Mark A. Socinski, M.D., director, lung cancer section, division of hematology/oncology, University of Pittsburgh, and lead investigator of Abraxane Phase II and Phase III lung cancer trials. “The FDA approval of Abraxane is exciting for healthcare professionals because it offers an important new treatment option for all types of non-small cell lung cancer patients, in an area that has seen few treatment advancements in recent years.”

    Celgene has filed additional regulatory submissions for the product in Japan, Australia, and New Zealand. This approval marks the second indication for Abraxane in the U.S. where the drug was first approved in 2005 for the treatment of metastatic breast cancer after failure of combination chemotherapy.

    According to Genomic Health, the incidence of non-small cell lung cancer totals about 171,000 cases per year.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »